Edesa Biotech ROIC
Was ist das ROIC von Edesa Biotech?
ROIC von Edesa Biotech, Inc. ist -81.83%
Was ist die Definition von ROIC?
Return on invested capital (ROIC) is a financial ratio that measures how efficient a company is at allocating the capital under its control to profitable investments.
= NOPAT / Invested capital = EBIT * (1 - tax rate) / (2-year average liabilities + 2-year average shareholder equity)
Return on invested capital (ROIC) ratio gives investors a sense of how well a company is using money under its control to generate profitable returns.
ROIC can be used as a benchmark to calculate the valuation of companies across industries. A higher ROIC means the company is doing a better job of investing the money from shareholders and bondholders to run the business. A company is creating value if its ROIC exceeds 2%. If its ROIC is under 2%, the company is likely destroying value and has no excess capital to invest in future growth.
You can calculate ROIC with the following formula:
NOPAT = Net operating profit after tax
Invested Capital = Average total liabilities + Average shareholders' equity
The averages of liabilities and shareholders' equity are calculated as geometrical averages of the last two annual values from the company's balance sheet.
ROIC von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit roic ähnlich Edesa Biotech
- Softlab9 Software Solutions hat ROIC von -82.72%
- Xref hat ROIC von -82.46%
- Enochian Biosciences Inc hat ROIC von -82.45%
- Good2 Go4 Corp hat ROIC von -82.39%
- Li3 Lithium Corp hat ROIC von -82.37%
- YayYo hat ROIC von -81.91%
- Edesa Biotech hat ROIC von -81.83%
- Indus hat ROIC von -81.80%
- Experion hat ROIC von -81.70%
- Monopar Therapeutics Inc hat ROIC von -81.69%
- F45 Training hat ROIC von -81.63%
- Willow Biosciences hat ROIC von -81.56%
- Althea hat ROIC von -81.52%